Stocks to Watch: Gemini Explorations, Inc. (OTCBB: GXPI), BrainStorm Cell Therapeutics Inc. (OTC BB:BCLI) , Benda Pharmaceutical, Inc. (OTC BB:BPMA) , Environmental Solutions Worldwide Inc. (OTC BB:ESWW) , Innova Robotics & Automation, Inc. (OTC BB:INRA)
Featured Stock: Gemini Explorations, Inc.
(OTCBB: GXPI)
Current Price (0.17)
SmallCap Sentinel: Two Billion Reasons
The informational report ``Investing in Gold Stocks for the SmallCap Investor'' has also been made available free of charge at http://www.smallcapsentinel.com/ and will address the rise of interest in gold related equities such as Barrick Gold Corporation (NYSE: ABX), NovaGold Resources (AMEX:NG), Yukon-Nevada Gold Corp. (
“It will be interesting to see with whom Gemini chooses to partner,”
The following reports are of interest to both Gemini investors and gold investors:
IPOdesktop research report
http://www.gaskinsco.com/linkto-gxpi.shtml
SmallCapVoice.com, audio interview featuring Gemini Explorations, Inc. CEO and President Michael Hill:
http://smallcapvoice.com/gxpi/gxpi-11-7-07.php
An investor report from Wall Street Stock Review:
http://www.wallstreetstockreview.com/
To have your company featured in SmallCap Sentinel please use the contact info below.
For more D.R. Clark perspective, visit http://www.clarkreport.com/
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
Information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy or offer to sell securities but is rather a paid advertisement provided for information purposes only and shouldn’t be used as the basis for investment decisions. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Equity Alliance International (http://www.equityallainceir.com/) on behalf of Gemini for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP’s ability to remain objective in communication regarding subject companies.
SmallCap Sentinel and its parent company Market Pathways do not independently verify or guarantee the veracity of any information linked from this report. Please contact the aforementioned entities directly for more information about their services and content.
For an in-depth analyst report, please visit: http://www.wallstreetstockreview.com/
BrainStorm Cell Therapeutics Inc.
(OTC BB:BCLI)
Current Price (0.43)
NEW YORK & PETACH TIKVAH, Israel--Nov 27--BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI - News), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that based on studies conducted to date, the Company’s adult stem cell therapies provide a safer approach at curing and treating neurodegenerative diseases than competitive therapies that rely on embryonic stem cells. In addition to the well-known ethical/religious concerns associated with embryonic stem cell therapies, experts are greatly concerned with the risk of the development of teratomas (or cancer) in patients as a result of the usage of embryonic stem cells. BrainStorm Cell Therapeutics is confident that its approach to stem cell treatments, using adult stem cells, eliminates this additional risk factor that embryonic stem cell treatments face. The Company expects that this will enable it to commercialize its products more quickly than its competitors, which will allow patients to benefit from its technologies and therapies more promptly. BrainStorm Cell Therapeutics Inc. is an emerging company developing adult stem cell therapeutic products, derived from autologous (self) bone marrow cells, for the treatment of neurodegenerative diseases. The NurOwn(TM) patent pending technology is based on discoveries made by the scientific team led by prominent neurologist Professor Eldad Melamed, Head of Neurology at
Benda Pharmaceutical, Inc.
(OTC BB:BPMA)
Current Price (0.81)
HUBEI PROVINCE, China--Nov 27--Benda Pharmaceutical, Inc. (“Benda” or the “Company”) (OTCBB:BPMA - News), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world’s first commercialized gene therapy medicine for the treatment of cancer, will host a conference call on Wednesday, November 28, 2007, to review third quarter 2007 earnings results. The conference call is scheduled for 9:00 a.m., Eastern Time. To participate in the call, please dial: Benda Pharmaceutical, Inc. (www.bendapharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.
Environmental Solutions Worldwide Inc.
(OTC BB:ESWW)
Current Price (0.56)
CONCORD, Ontario--Nov 27--Environmental Solutions Worldwide Inc. (ESW) (OTCBB:ESWW - News) (FWB:EOW) announced today that its wholly owned subsidiary ESW Canada Inc. has become the exclusive North America distributor for Notox’s Silicon Carbide Diesel Particulate Filters (DPF’s). Headquartered in Concord, Ontario, Environmental Solutions Worldwide, Inc. is a publicly traded company engaged through its wholly owned subsidiaries ESW Canada, Inc. and ESW America, Inc. (the ESW Group of Companies) in the design, development, ISO 9001:2000 certified manufacturing and sales of technologies for both the environmental control and military sectors. The ESW Group of Companies currently manufacture and market a diversified line of catalytic emission control products and support technologies for diesel, gasoline and alternative fueled engines. The ESW Group of Companies also operates a comprehensive EPA/CARB & MSHA recognized emissions testing and verification laboratory.
Innova Robotics & Automation, Inc.
(OTC BB:INRA)
Current Price (0.01)
REDMOND, WA---Nov 27, 2007 -- CoroWare, an Innova Robotics & Automation, Inc. (OTC BB:INRA.OB - News) company, today announced that it recently entered into a distribution agreement with RobotShop Inc., a distributor of personal and domestic robots. Fort Myers, Fla.-based Innova Robotics & Automation (OTC BB:INRA.OB - News) pioneers innovative control and communication solutions that make robotics and automated systems more productive, powerful, and profitable for customers in the telecommunications, manufacturing, aerospace, research, and service industries. The company is chartered to continue expanding its growing suite of technologies through acquisitions and organic growth. Innova operates through four subsidiaries, Robotic Workspace Technologies (RWT), CoroWare Technologies, Altronics Service, and Innova Robotics, which offer convergent technology and expertise that bridges robots, CNC machines, facilities, and business systems for greater functionality and ROA. Visit Innova online at www.InnovaRoboticsAutomation.com.
WallStreetStockReview.com is owned and operated by Iron Consulting.
Verify all claims and do your own due diligence. Iron Consulting profiles are not a solicitation or recommendation to buy, sell or hold securities. Iron Consulting is not offering secu rities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Iron Consulting is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b),WallStreetStockReview.com is owned and operated by Iron Consulting. Iron Consulting www.ironconsultinginc.com has receive seventy two thousand dollars in 2006 and thirty six thousand in 2007 from Equity Alliance Intl. www.equityallianceir.com for a internet marketing program. Neither Iron Consulting nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Iron Consulting receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Iron Consulting statements and opinions and such statements and opinions cannot be considered independent. Iron Consulting and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements ar e made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Iron Consulting services are often paid for using free-trading shares. Iron Consulting may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
